Swiss biotech spin-off from ETH Zurich, addresses a critical challenge in drug development: improving how medicines are formulated and delivered to enhance efficacy and patient outcomes. Its proprietary polymer platform enables faster formulation optimization and more precise delivery of oral and long-acting injectable drugs.
InkVivo has raised €1.2M across 1 funding round from 3 investors, most recently a Pre-Seed round in Aug 2025. Based in Zurich, Switzerland; active in Healthtech. Data as of 7 Aug 2026.
Timing: in window vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2025-08-13 | Pre-Seed | €1.2M |
| Business Angels,Claves Investments,TiVentures |
| View deal → |
